What are the VA rating percentages for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

Monoclonal Gammopathy of Undetermined Significance (MGUS) (DC 7703) is rated at 0%, 10%, 30%, 60%, 100% under 38 CFR § 4.117, DC 7703. Condition in remission or asymptomatic with stable blood counts.

What happens during a C&P exam for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

Do NOT stretch, warm up, or take pain medication before your exam. The VA needs your baseline limitation. Report your WORST day. DeLuca v. Brown requires documentation of functional loss during flare-ups.

← All Condition Guides

CLAIM RECON INTEL

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Q: What rates 0% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7703?

Under 38 CFR § 4.117, DC 7703 (DC 7703), a 0% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Condition in remission or asymptomatic with stable blood counts.

Q: What rates 10% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7703?

Under 38 CFR § 4.117, DC 7703 (DC 7703), a 10% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Mild symptoms requiring continuous medication; or hemoglobin 10g/dL or less with anemia symptoms.

Q: What rates 30% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7703?

Under 38 CFR § 4.117, DC 7703 (DC 7703), a 30% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Moderate symptoms with frequent transfusions or regular treatment; or recurrent infections from immunodeficiency.

Q: What rates 60% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7703?

Under 38 CFR § 4.117, DC 7703 (DC 7703), a 60% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Severe symptoms requiring frequent hospitalization, transfusions, or significant organ involvement.

Q: What rates 100% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7703?

Under 38 CFR § 4.117, DC 7703 (DC 7703), a 100% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Active disease requiring continuous intensive treatment or with life-threatening complications.

Q: What evidence do I need for a Monoclonal Gammopathy of Undetermined Significance (MGUS) VA claim?

Key evidence for a Monoclonal Gammopathy of Undetermined Significance (MGUS) claim includes: Service treatment records showing injury or complaints; Imaging (X-ray, MRI, CT); Range of motion measurements; Flare-up documentation per Sharp v. Shulkin; Buddy statements describing limitations. All evidence should document both the condition and its impact on daily functioning.

DC 770338 C.F.R. § 4.117

Diagnostic Code

DC 7703

38 C.F.R. § 4.117

Rating Range

0–100%

5 severity tiers

Source

Referenced

38 C.F.R. Part 4

Monoclonal Gammopathy of Undetermined Significance (MGUS) is rated by the U.S. Department of Veterans Affairs under DC 7703 of 38 CFR § 4.117, DC 7703 across 5 severity tiers (0% / 10% / 30% / 60% / 100%). Service connection requires (1) a current diagnosis, (2) an in-service event, injury, or exposure, and (3) a medical nexus opinion linking the two under 38 C.F.R. § 3.303.

Educational tool only. Not legal or medical advice. Not affiliated with the VA.

Overview

Blood condition where an abnormal protein (monoclonal protein or M protein) is found in the blood. Can progress to multiple myeloma or other blood cancers. Presumptive for Agent Orange exposure under the PACT Act. Requires lifelong monitoring.

Rating Criteria

Condition in remission or asymptomatic with stable blood counts.

10%

Mild symptoms requiring continuous medication; or hemoglobin 10g/dL or less with anemia symptoms.

30%

Moderate symptoms with frequent transfusions or regular treatment; or recurrent infections from immunodeficiency.

60%

Severe symptoms requiring frequent hospitalization, transfusions, or significant organ involvement.

100%

Active disease requiring continuous intensive treatment or with life-threatening complications.

03Key Evidence

—Service treatment records showing injury or complaints

—Imaging (X-ray, MRI, CT)

—Range of motion measurements

—Flare-up documentation per Sharp v. Shulkin

—Buddy statements describing limitations

—Prescription history

—Physical therapy records

—Employment impact documentation

04C&P Exam Tips

1Do NOT stretch, warm up, or take pain medication before your exam. The VA needs your baseline limitation.

2Report your WORST day. DeLuca v. Brown requires documentation of functional loss during flare-ups.

3Tell the examiner about flare-ups: frequency, duration, estimated ROM loss. Sharp v. Shulkin (2017) requires estimates.

4Request active, passive, weight-bearing, and non-weight-bearing ROM testing per Correia v. McDonald (2016).

5If you use assistive devices (brace, cane), bring them.

6Describe daily activity impact: work, sleep, household tasks.

Tools

Rating Calculator →Secondaries Explorer →C&P Exam Prep →PACT Act Scanner →2026 Rates →

Sources & Editorial

Rating criteria reference 38 C.F.R. Part 4 (Schedule for Rating Disabilities). This entry has not yet undergone editorial review against the live regulation text — consult the authoritative source directly before relying on the criteria shown.

View 38 C.F.R. Part 4 on eCFR →Editorial Standards →Suggest a correction →

EDUCATIONAL TOOL ONLY. NOT LEGAL OR MEDICAL ADVICE.
NOT AFFILIATED WITH THE U.S. DEPARTMENT OF VETERANS AFFAIRS.
CLAIM RECON 2026

LOADING